12:57 PM EDT, 08/12/2025 (MT Newswires) -- Biogen (BIIB) Chief Executive Officer Chris Viehbacher sees Novo Nordisk's ( NVO ) study evaluating its weight-loss drug for Alzheimer's disease as an opportunity to potentially create a more potent therapy, Bloomberg said Tuesday, citing the CEO.

If Novo's study succeeds, then Biogen "might" do trials looking at the two drugs in combination, Viehbacher said during an interview with Bloomberg, adding that the timeline might not make sense considering that studies on Alzheimer's disease take years to complete.

Biogen is aiming to offset the decline of its multiple sclerosis franchise, which faces competition from cheaper generic drugs, with the growth of its Alzheimer's drug Leqembi, Bloomberg said.

Biogen did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 129.60, Change: +1.60, Percent Change: +1.25